ArticleAnalytical chemistry2026
Immunomagnetic Sample Preparation Targeting Host- and Viral-Derived Antigens for HIV-1 Isolation from Limited Plasma Volumes.
Article in Analytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Rapid and accurate HIV detection is crucial for early diagnosis and viral load (VL) monitoring in individuals receiving antiretroviral therapy (ART). To address the challenge of limited sample volume, we developed a novel immunomagnetic sample preparation method to isolate HIV-1 virions from 25 μL of plasma─about one-tenth of a small finger-prick sample. Immunomagnetic conjugates were produced by coupling antimouse IgG magnetic beads with mouse IgG antibodies targeting host- and virus-derived antigens on the HIV surface. In buffer spiked with inactivated HIV-1 grown in the HUT-78 cell line, these conjugates achieved capture efficiencies of 45-97%. Optimization of conjugate concentrations (0.71-5.71 mg/mL) improved capture efficiency by 19%, with 15 min identified as the optimal capture time. In spiked plasma (25 μL), immunoconjugates targeting different surface antigens captured inactivated HIV-1 across inputs of 148-53,145 RNA copies/25 μL (5,920-2,125,800 RNA copies/mL) with consistent efficiencies ranging from 41% to 100%. In clinical specimens from individuals living with HIV with VLs ranging from 100,000 to >1 million copies/mL, capture efficiencies varied from 5% to 60% depending on the conjugate used. Notably, combining CD44 and CD46 targeting conjugates, which recognize different surface markers, did not enhance virion capture, suggesting the coexpression of targeted antigens on HIV-1. Together, our results established immunomagnetic isolation as a promising approach for HIV-1 sample preparation, enabling more accessible, sensitive, and rapid VL quantification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.